Source:http://linkedlifedata.com/resource/pubmed/id/10085066
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
1999-4-29
|
pubmed:abstractText |
Upon exposure to stress signals, the p53 tumor suppressor protein is stabilized and induces growth suppression. p53 activities are efficiently inhibited by the Mdm2 oncoprotein through an autoregulatory feedback loop. In addition, Mdm2 promotes p53 degradation, thereby terminating its growth inhibitory signal. Hence, p53 exerts its effects during the interval between p53 activation and the subsequent inhibition by Mdm2. Modulation of this interval by regulatory proteins may determine the extent and duration of p53 activity. Recent studies have shown that the c-Abl protein-tyrosine kinase binds p53 and enhances its transcriptional activity. Here we provide an explanation for the cooperation between these proteins. We demonstrate that c-Abl increases the expression level of the p53 protein. The enhanced expression is achieved by inhibiting Mdm2-mediated degradation of p53. This provides a likely mechanistic explanation for the findings that c-Abl overcomes the inhibitory effects of Mdm2 on p53-mediated transcriptional activation and apoptosis. These results suggest that c-Abl modulates the time window within which p53 remains active. The ability of c-Abl to neutralize the inhibitory effects of Mdm2 on p53 may be important for its growth inhibitory function.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Mdm2 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
26
|
pubmed:volume |
274
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
8371-4
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:10085066-Animals,
pubmed-meshheading:10085066-Apoptosis,
pubmed-meshheading:10085066-Cell Line,
pubmed-meshheading:10085066-Genes, Reporter,
pubmed-meshheading:10085066-Mice,
pubmed-meshheading:10085066-Nuclear Proteins,
pubmed-meshheading:10085066-Promoter Regions, Genetic,
pubmed-meshheading:10085066-Proto-Oncogene Proteins,
pubmed-meshheading:10085066-Proto-Oncogene Proteins c-abl,
pubmed-meshheading:10085066-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:10085066-Transcriptional Activation,
pubmed-meshheading:10085066-Transfection,
pubmed-meshheading:10085066-Tumor Suppressor Protein p53
|
pubmed:year |
1999
|
pubmed:articleTitle |
c-Abl neutralizes the inhibitory effect of Mdm2 on p53.
|
pubmed:affiliation |
Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, Jerusalem 91120, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|